Evidence map›Paper›PMID 36305848›Full record

ArticleCancer medicine2023

BDP1 as a biomarker in serous ovarian cancer.

Stephanie Cabarcas-Petroski, Gabriella Olshefsky, Laura Schramm

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Stephanie Cabarcas-PetroskiBiology Department, Pennsylvania State Beaver, Pennsylvania State University, Monaca, Pennsylvania, USA.ORCID 0000-0002-2310-5273
Gabriella OlshefskyGarden City High School, Garden City, New York, USA.
Laura SchrammBiology Department, St. John's University, Queens, New York, USA.ORCID 0000-0002-3587-2912
Garden City Community College · USPennsylvania State University · USSt. John's University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTFIIIB, an RNA polymerase III specific transcription factor has been found to be deregulated in human cancers with much of the research focused on the TBP, BRF1, and BRF2 subunits. To date, the TFIIIB specific subunit BDP1 has not been investigated in ovarian cancer but has previously been shown to be deregulated in neuroblastoma, breast cancer, and Non-Hodgkins lymphoma.

resultsUsing in silico analysis of clinically derived platforms, we report a decreased BDP1 expression as a result of deletion in serous ovarian cancer and a correlation with higher and advanced ovarian stages. Further analysis in the context of TP53 mutations, a major contributor to ovarian tumorigenesis, suggests that high BDP1 expression is unfavorable for overall survival and high BDP1 expression occurs in stages 2, 3 and 4 serous ovarian cancer. Additionally, high BDP1 expression is disadvantageous and unfavorable for progression-free survival. Lastly, BDP1 expression significantly decreased in patients treated with first-line chemotherapy, platin and taxane, at twelve-month relapse-free survival.

conclusionsTaken together with a ROC analysis, the data suggest BDP1 could be of clinical relevance as a predictive biomarker in serous ovarian cancer. Lastly, this study further demonstrates that both the over- and under expression of BDP1 warrants further investigation and suggests BDP1 may exhibit dual function in the context of tumorigenesis.

Indexed as

Ovarian NeoplasmsSaccharomyces cerevisiae ProteinsTATA-Binding Protein Associated FactorsBiomarkersCarcinogenesisFemaleHumansNeoplasm Recurrence, LocalTranscription Factor TFIIIBBDP1 protein, humanBiomarkersBRF1 protein, humanBRF2 protein, humanSaccharomyces cerevisiae ProteinsTATA-Binding Protein Associated FactorsTranscription Factor TFIIIBBDP1ovarian cancer biomarkersRNA polymerase IIIserous ovarian cancerTFIIIB

Identifiers

PMID36305848
PMCPMC10028122
OpenAlexW4307466665

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read76
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.